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Background: Diffuse myocardial fibrosis may be quantified with cardiovascular magnetic resonance (CMR) by
calculating extra-cellular volume (ECV) from native and post-contrast T1 values. Accurate ECV calculation is
dependent upon the contrast agent having reached equilibrium within tissue compartments. Previous studies have
used infusion or single bolus injections of contrast to calculate ECV. In clinical practice however, split dose contrast
injection is commonly used as part of stress/rest perfusion studies. In this study we sought to assess the effects of
split dose versus single bolus contrast administration on ECV calculation.
Methods: Ten healthy volunteers and five patients ( 4 ischaemic heart disease, 1 hypertrophic cardiomyopathy)
were studied on a 3.0 Tesla (Philips Achieva TX) MR system and underwent two (patients) or three (volunteers)
separate CMR studies over a mean of 12 and 30 days respectively. Volunteers underwent one single bolus contrast
study (Gadovist 0.15mmol/kg). In two further studies, contrast was given in two boluses (0.075mmol/kg per bolus)
as part of a clinical adenosine stress/rest perfusion protocol, boluses were separated by 12 minutes. Patients
underwent one bolus and one stress perfusion study only. T1 maps were acquired pre contrast and 15 minutes
following the single bolus or second contrast injection.
Results: ECV agreed between bolus and split dose contrast administration (coefficient of variability 5.04%, bias
0.009, 95% CI −3.754 to 3.772, r2 = 0.973, p = 0.001)). Inter-study agreement with split dose administration was good
(coefficient of variability, 5.67%, bias −0.018, 95% CI −4.045 to 4.009, r2 = 0.766, p > 0.001).
Conclusion: ECV quantification using split dose contrast administration is reproducible and agrees well with
previously validated methods in healthy volunteers, as well as abnormal and remote myocardium in patients. This
suggests that clinical perfusion CMR studies may incorporate assessment of tissue composition by ECV based on T1
mapping.Background
Expansion and composition change of the myocardial
extra-cellular matrix (ECM) is seen in a range of myocar-
dial diseases and correlates with measures of systolic and
diastolic function [1-5]. Cardiovascular magnetic reson-
ance (CMR) late gadolinium enhancement (LGE) imaging
is well suited for the detection of focal myocardial scar
that characterises a number of disease processes [6,7].* Correspondence: s.plein@leeds.ac.uk
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unless otherwise stated.However this technique relies upon the presence of
healthy myocardium to detect scar, and as a result is lim-
ited in the detection of diffuse myocardial disease pro-
cesses where global myocardial ECM expansion occurs.
Longitudinal relaxation time (T1) mapping allows quan-
titative characterisation of the myocardium, thereby enab-
ling detection of diffuse myocardial disease processes that
has previously required cardiac biopsy [8,9]. Furthermore,
the ability to accurately define myocardial composition al-
lows for the detection of sub-clinical disease states and
may enable the effects of intervention on tissue compos-
ition to be determined non-invasively [10].tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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of an extra-cellular contrast agent allows the relative vol-
umes of the intra-cellular and extra-cellular components
of myocardial tissue to be quantified as long as equilib-
rium between the extra-cellular compartments (intersti-
tium and blood) has been reached. Equivalence of
primed slow intra-venous infusion and bolus only ad-
ministration of contrast agent has been demonstrated
previously [11,12]. However, stress perfusion imaging is
an expanding area of CMR [13] now included in inter-
national practice guidelines [14]. During stress perfusion
CMR studies, contrast agent delivery is split between
rest and stress imaging. Integrating T1 mapping and
ECV calculation in such a clinical protocol requires
knowledge of the effects of split contrast injection on
the derived measurements. Therefore we aimed to deter-
mine the effects of split versus single bolus contrast ad-
ministration on ECV, and to assess the inter-study
variability of ECV measured on split contrast adminis-
tration CMR studies.
Methods
The research protocol was approved by the local ethics
committee and all subjects gave written informed con-
sent. All studies were performed at a single centre
equipped with a 3 T MRI scanner (Achieva TX, Philips
Healthcare, Best, The Netherlands) using RF shimming
and a 32-channel cardiac phased array receiver coil.
Volunteer scanning
A total of ten healthy volunteers were recruited to
undergo CMR. Subjects were excluded if they had a his-
tory of cardiac disease, hypertension, renal impairment,
diabetes or contra-indication to CMR.
All subjects underwent a total of three CMR studies
on separate days.
Study 1. Single bolus: In one CMR study, the contrast
agent (Gadovist, Bayer Schering Pharma, Berlin-Wedding,
Germany) was administered as a single bolus (0.15 mmol/
kg) with post-contrast T1 mapping acquired 15 minutes
later.
Study 2. Split dose: Contrast was administered as a
split doses (0.075 mmol/kg twice) as part of an adeno-
sine stress perfusion protocol. For stress perfusion,
intra-venous adenosine was administered at 140 mcg/
kg/min, via an intra-venous cannula sited in the ante-
cubital fossa, for a minimum of three minutes and until
an appropriate haemodynamic response had occurred.
Contrast agent was delivered at a dose of 0.075 mmol/kg
at peak haemodynamic stress. For rest perfusion, the
same contrast injection regime was repeated twelve mi-
nutes later. A total Gadovist dose of 0.15 mmol/kg was
administered. Post-contrast T1 mapping was performed
15 minutes after the second contrast administration.Study 3. Split dose: Split dose stress perfusion CMR
study as 2.
Patient scanning
A total of five patients that had undergone a clinically
indicated, non-urgent, adenosine stress perfusion CMR
were recruited if they exhibited an area of enhancement
on LGE imaging on the clinical study, which included
native T1 map and 15 minute post contrast T1 map as
per our local protocol. Patients were then recalled for
one single bolus CMR study on a separate day in keep-
ing with the above protocols.
CMR protocol
In each study, the cardiac long-axis was located as per
standard practice using balanced steady-state free pre-
cession pulse (bSSFP) cine images. Cine imaging was
performed using a contiguous stack of parallel short-axis
slices covering the whole left ventricle (LV), with a
bSSFP pulse sequence (echo time (TE) 1.3 ms; repetition
time (TR) 2.6 ms; flip angle 40°, spatial resolution 1.6 ×
2.0 × 10 mm, 40 phases per cardiac cycle).
For all studies, contrast was delivered via a peripheral
cannula, followed by a 20 ml saline flush delivered by au-
tomated injector (Medrad Inc, Warrendale, Pennsylvania,
USA) at 5 ml/second.
Native and 15 minute post-contrast data for T1 value es-
timation were obtained using breath-held Modified Look-
Locker Inversion recovery (MOLLI) acquisition [10,15,16].
Images were acquired in the central slice of a ‘3 of 5’ ap-
proach [17]. An ECG triggered 5b(3 s)3b MOLLI balanced
turbo gradient recalled echo (GRE) acquisition method
was used (voxel size 1.98×1.98×10 mm3 (reconstructed to
1.25×1.25 mm), single-shot, sensitivity encoding (SENSE)
factor 2, trigger delay set for end-diastole, flip angle 35°, ac-
quisition duration per image 170-185 ms (dependent upon
FOV) a range of inversion times are calculated by the sys-
tem in order to provide good sampling of T1 recovery.
Perfusion imaging acquisition used a spoiled turbo
GRE sequence (echo time (TE) 2.8 ms; repetition time
(TR) 1.28 ms; flip angle 15°, acquired spatial resolution
2.42×2.42 × 10 mm) in three 10 mm short axis slices
with a 148×148 matrix, FOV 300–420, sensitivity encod-
ing factor 2.4, half scan factor of 0.65 and a saturation
pre-pulse delay of 80 ms.
LGE imaging was performed at 7–10 minutes follow-
ing final contrast dose (inversion recovery-prepared T1
weighted gradient echo, inversion time according to
Look-Locker scout, TR/TE/flip angle 3.7/2.0/25 degrees,
spatial resolution 1.54 × 1.75 × 10 mm).
Image analysis
Study images were saved as Digital Imaging and Com-
munications in Medicine (DICOM) format. T1 values
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tion correction on CMR42 (Circle Cardiovascular Im-
aging Inc, Calgary, Alberta, Canada). Mis-registration
was avoided by visually comparing left and right ven-
tricular anatomical features (papillary muscles, trabecu-
lations) any mis-registered images were discarded. In
volunteers a narrow region of interest (ROI) in the
infero-septum of the mid-ventricular slice was drawn as
per Puntmann [18] in an effort to minimise potential
artefact induced by epicardial cardiac vessels in the an-
terior and lateral walls. In patient studies two separate
ROIs were drawn sampling:
1. the area displaying visual enhancement on the LGE
acquisition; matched using standard image planning
techniques and left and right ventricular anatomical
features.
2. remote myocardium (preferentially the infero-septum
as in volunteer studies).
The blood pool contour was drawn in the centre of the
LV cavity on the same slice away from any papillary
muscle. Signal intensity was measured from each MOLLI
source image and T1 estimated based on the mean signal
from myocardial and blood pool ROIs. ECV was calcu-
lated using the formula:
ECV ¼ 1 − Hctð Þ R1 myo preð Þ−R1 myo postð Þ
R1 blood preð Þ−R1 blood postð ÞWhere R1¼1=T1
Statistical analysis
Statistical analysis was performed using IBM SPSS® Sta-
tistics 21.0 (IBM Corp., Armonk, NY). Unless otherwise
stated the results are presented as mean ± standard devi-
ation (SD). Reproducibility and agreement was assessed
by coefficient of variation and Bland Altman plot. Nor-
mality of distribution was determined with Kolmogarov-
Smirnov testing, normality was assumed with a value ofTable 1 Subject characteristics
Healthy volunteers (
Age 26.6 ± 2.8
Gender (M:F) 7 : 3
Underlying Cardiac Disease
Mean Rest Systolic Blood Pressure (mmHg) 111 ± 7
Mean Rest Diastolic Blood Pressure (mmHg) 55 ± 6
Mean Rest Heart Rate (bpm) 61.4 ± 5.2
Mean Stress Heart Rate Increase 22.6 ± 7.6
BSA indexed LVEDV (ml/kg/m2) 101.3 ± 12.3
BSA indexed LV Mass (g/kg/m2) 51.5 ± 7.1
LV EF % 57 ± 2
RV EF % 54 ± 2>0.2. Correlation was assessed with Pearson’s correlation
coefficient.
Results
Demographic characteristics of the study volunteers are
as presented in Table 1. The mean age of volunteers was
26.6 yrs ± 2.8, 7 of 10 volunteers were men. Body surface
area (BSA) corrected LVEDV (101 ± 12 ml/m2), LV mass
(52 ± 7 g/m2) and ejection fraction (57% ± 2) were nor-
mal. All volunteers had normal right ventricular function
and demonstrated no hyper-enhancement on late gado-
linium enhancement images. All volunteers had an ap-
propriate response to adenosine, with mean resting
heart rate of 61.4 ± 5.2 beats per minute that increased
on stress perfusion by 22.6 ± 7.6 beats per minute. Stress
perfusion images were assessed qualitatively and no perfu-
sion defects were identified. Split dose administration con-
trast agent doses were separated by 12.0 ± 3.7 minutes.
Patient characteristics are as displayed in Table 1.
Mean patient age was 59 yrs ± 13.3, 4 of 5 patients were
men, body surface area (BSA) corrected LVEDV (96 ±
36 ml/m2), LV mass (64 ± 20/m2) and ejection fraction
(42% ± 13). Patient pathologies were: 4 chronic ischaemic
heart disease with established myocardial infarction; 1
hypertrophic cardiomyopathy. All patients had extensive
LGE, and no inducible perfusion defects on stress perfu-
sion imaging outwith the area of LGE.
29 of 30 sets of volunteer mid-ventricular short axis
MOLLI acquisitions were available for final analysis; in
one MOLLI an acquisition error prohibited analysis. 10 of
10 patient MOLLI acquisitions were suitable for analysis.
There was a strong positive correlation between ECV
calculated following single or split bolus contrast admin-
istration in healthy volunteers, as well as abnormal and
remote myocardium in patients (coefficient of variability
5.04%; bias 0.009, 95% CI −3.754 to 3.772, r2 = 0.973,
p = 0.001)). Bland-Altman plot of the data set can be
seen in Figure 1.n = 10) Patients (n = 5)
59 ± 13.3
4 : 1









Figure 1 Bland Altman plot of agreement between ECV estimated using single bolus and split-dose contrast administrations in
patients and healthy volunteers (bias 0.009, 95% CI −3.754 to 3.772, r2 = 0.973, p = 0.001). Bland Altman: Shaded diamond: Pathological
Myocardium; Diamond: Remote myocardium; Circle: Healthy Volunteer. Correlation Plot: Circle: All study subjects.
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dose administration visits was good in the 10 volun-
teers studied (coefficient of variability 5.67%, r2 = 0.766,
p < 0.001). Bland-Altman plot can be seen in Figure 2
(bias −0.018, 95% CI −4.045 to 4.009).
Discussion
The insights that T1 mapping offers into tissue compos-
ition are increasingly applied as a research tool. T1 map-
ping is also being integrated into clinical protocols,
particularly in the investigation of unexplained left ven-
tricular hypertrophy. Consequently, comprehensive CMR
protocols that interrogate not only cardiac structure, func-
tion and perfusion but also tissue composition in one
protocol have great potential clinical value.
Previous studies have shown that ECV calculated using
either an infusion or bolus of contrast agent [12] is re-
producible, and correlates well with fibrosis measured
on myocardial biopsy specimens [19]. However until thisFigure 2 Bland Altman plot of agreement of ECV estimates between
(bias −0.018, 95% CI −4.045 to 4.009, r2 = 0.757, p = 0.001).time it was not known if split dose contrast administra-
tion, as used in adenosine stress perfusion protocols af-
fects, ECV estimation and how this correlates with
previously validated methods.
Given that reliable ECV calculation requires steady
state of contrast agent concentration, split dose adminis-
tration may have given rise to different estimates against
single bolus administration or a continuous contrast in-
fusion. Any such differences would have prevented the
application of established normal ranges that have been
published over recent years to subjects undergoing stress
perfusion protocols [8,9,19-21]. It was also conceivable
that vasodilator effects of adenosine stress may have led
to different contrast distribution with the myocardium
and peripheral tissues. Persistent vasodilation at the
time of the second MOLLI, as a consequence of adeno-
sine administration would lead to a genuine increase of
ECV due to increased capillary plasma volume. How-
ever the vasodilatory effects of adenosine are bothvisit 1 and 2 using split-dose administration in healthy volunteers
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time of rest perfusion acquisition and following that,
the second MOLLI.
This study has now shown that ECV estimation with
split dose contrast administration as part of a stress/rest
perfusion CMR protocol agrees well with bolus adminis-
tration in healthy volunteers. Reproducibility and inter-
study agreement was good for split dose ECV calculations
and in line with that previously published for ECV calcula-
tion following bolus contrast administration [12].
Previously published data suggested that bolus con-
trast administration may underestimate ECV at values of
>40% [12]. However in this study we have examined 5
patients with extensive LGE enhancement and grossly
elevated ECV due to chronic myocardial infarction and
cardiomyopathy and found equivalence between the
techniques. This suggests that ECV calculation is reliable
across a range of values using either method of contrast
administration.Limitations
This study was performed in a limited number of healthy
volunteers and patients. It has previously been shown that
at fifteen minutes contrast equilibrium may not have been
reached for post contrast T1 mapping, especially in indi-
viduals with higher ECVs. [12] This study has attempted
to address this point specifically, however no patients with
the most elevated ECVs (eg cardiac amyloidosis) were
studied, due in part to the demands of returning for a
non-clinically indicated research CMR study. In spite of
this we have shown equivalence of these techniques in
ECV calculation up to an ECV of 48%.
This study investigated one particular MOLLI acquisi-
tion scheme which is consistent with international recom-
mendations. However, other methods have been published
and as yet there is no firm MOLLI scheme recommenda-
tion. It is difficult to select the ideal T1 mapping se-
quence as different sequences may perform differently
depending upon the T1 of the tissue studied. Conse-
quently the demonstration of the inter-study reproduci-
bility of locally adopted sequences, in line with SCMR
guidance, is important.Conclusion
Split dose contrast T1 mapping, in keeping with a stress
perfusion protocol, is reproducible and agrees with bolus
contrast administration. This suggests ECV measure-
ment maybe incorporated into stress perfusion protocols
in both clinical and research CMR.Competing interests
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